Therini Bio Expands Series A to $75M with Fresh Funds for Neurodegenerative Research
Deal News | May 14, 2025 | SV Health Investors, LLC
In a stride to tackle neurodegenerative diseases, Therini Bio secured a $39 million Series A extension financing, enlarging its total Series A raise to $75 million. The extension included new investors Angelini Ventures and Apollo Health Ventures alongside existing stakeholders such as SV Health Investors Biotech Fund. The proceeds will fund Phase 1b trials of their pioneering candidate, THN391, aimed at Alzheimer’s Disease and Diabetic Macular Edema, and support the development of a fibrin/VEGF bispecific. Therini Bio specializes in therapies that target the root causes of neurodegeneration, focusing on fibrin deposits that exacerbate neuroinflammation. Their lead candidate, THN391, which demonstrated efficacy in preclinical studies, is awaiting further clinical validation with the latest financing. CEO Tara Nickerson noted the importance of the investors’ support in advancing the company’s innovative therapeutic approach.
Sectors
- Biotechnology
- Pharmaceuticals
- Venture Capital
Geography
- United States – Therini Bio is a US-based company and the article includes references to investors such as SV Health Investors Biotech Fund, highlighting the significance in the American biotechnology and venture capital landscape.
Industry
- Biotechnology – The article discusses a biotechnology company, Therini Bio, which is engaged in developing new immunotherapies for neurodegenerative diseases.
- Pharmaceuticals – Therini Bio is involved in clinical trials for its drug candidate, THN391, targeting Alzheimer’s Disease and Diabetic Macular Edema.
- Venture Capital – The article focuses on funding activities involving venture capitalists such as Angelini Ventures and Apollo Health Ventures investing in Therini Bio.
Financials
- $39 million – The amount raised by Therini Bio in its Series A extension financing.
- $75 million – The total amount raised by Therini Bio in its entire Series A funding round.
Participants
| Name | Role | Type | Description |
|---|---|---|---|
| Therini Bio, Inc. | Target company | Company | A clinical-stage biotech company developing immunotherapies for neurodegenerative diseases driven by vascular dysfunction. |
| SV Health Investors, LLC | Investor | Company | A private equity firm and existing investor in Therini Bio's Series A round. |
| Angelini Ventures | Investor | Company | A new investor participating in Therini Bio's Series A extension financing. |
| Apollo Health Ventures | Investor | Company | A new investor that joined the Series A extension round for Therini Bio. |
| Tara Nickerson, Ph.D. | Chief Executive Officer | Person | CEO of Therini Bio with a significant background in biotech financing. |
| Thomas Thestrup | Senior Principal | Person | Senior Principal at Angelini Ventures who led the investment in Therini Bio. |
| Eli Lilly and Company | Investor | Company | An existing investor in Therini Bio's Series A funding. |